CKD-602 Chong Kun Dang

Mirjam Crul*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II trials of CKD-602 were underway.

Original languageEnglish
Pages (from-to)1455-1459
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Issue number12
Publication statusPublished - 1 Dec 2003

Cite this